ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
US Tech 100
18,064.80
0.02%
Dow Jones
38,686.32
1.51%
Brent Oil
81.295
0.00%
Bitcoin
68,112.18
0.57%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Immunocore Holdings PLC (IMCR)

  7. Immunocore Holdings PLC (IMCR) News

IMCR

Immunocore (IMCR)

Immunocore Holdings PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IMCR
DateTimeSourceHeadlineSymbolCompany
06/01/20248:00AMGlobeNewswire Inc.Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial responseNASDAQ:IMCRImmunocore Holdings PLC
05/31/20244:21PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
05/31/20244:05PMGlobeNewswire Inc.Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024NASDAQ:IMCRImmunocore Holdings PLC
05/30/20244:00PMGlobeNewswire Inc.Immunocore to present at the Jefferies Global Healthcare ConferenceNASDAQ:IMCRImmunocore Holdings PLC
05/29/20247:00AMGlobeNewswire Inc.Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanomaNASDAQ:IMCRImmunocore Holdings PLC
05/28/20244:17PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
05/28/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
05/28/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
05/28/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
05/28/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
05/23/20244:50PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
05/08/20247:13AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
05/08/20247:00AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMCRImmunocore Holdings PLC
05/08/20247:00AMGlobeNewswire Inc.Immunocore reports first quarter financial results and provides a business updateNASDAQ:IMCRImmunocore Holdings PLC
04/24/202410:00AMGlobeNewswire Inc.Immunocore announces upcoming presentation and posters at ASCO 2024NASDAQ:IMCRImmunocore Holdings PLC
04/04/20244:00PMGlobeNewswire Inc.Immunocore to present at upcoming investor conferencesNASDAQ:IMCRImmunocore Holdings PLC
03/05/20244:30PMGlobeNewswire Inc.Immunocore presented two posters at CROI 2024NASDAQ:IMCRImmunocore Holdings PLC
03/01/20247:00AMGlobeNewswire Inc.Immunocore to present at upcoming investor conferencesNASDAQ:IMCRImmunocore Holdings PLC
02/28/20244:19PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMCRImmunocore Holdings PLC
02/28/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
02/28/20247:34AMGlobeNewswire Inc.Immunocore reports fourth quarter and full year 2023 financial results and provides a business updateNASDAQ:IMCRImmunocore Holdings PLC
02/28/20247:33AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IMCRImmunocore Holdings PLC
02/26/20246:46PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:IMCRImmunocore Holdings PLC
02/22/20247:00AMGlobeNewswire Inc.Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trialNASDAQ:IMCRImmunocore Holdings PLC
02/21/20244:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
02/21/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
02/21/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
02/21/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
02/21/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMCRImmunocore Holdings PLC
02/21/20247:00AMGlobeNewswire Inc.Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024NASDAQ:IMCRImmunocore Holdings PLC
 Showing the most relevant articles for your search:NASDAQ:IMCR

Your Recent History

LSE
REDC
Red Capital
BIT
SIT
Sit S.p.A
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved